This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

SIGA Shares Leap On Likely Gov't Contract

Stocks in this article: SIGA

NEW YORK (AP) â¿¿ Shares of biodefense company SIGA Technologies Inc. rose more than 19 percent Tuesday after government actions signaled that the company is a top contender to supply millions of doses of smallpox treatment for a national stockpile.

THE SPARK: In October, SIGA won a version of the deal that required that some of the money go to small businesses. However, a smaller competitor protested to the Small Business Administration. The SBA agreed with the smaller company, Chimerix Inc., based in Durham, N.C., calling SIGA "other than small." Last week, however, the government scrapped its request for proposals. A replacement RFP was nearly identical, but omitted the rules about small business participation.

Analysts said the new RFP, issued on behalf of the Biomedical Advanced Research and Development Authority, is designed to make SIGA the only viable bidder.

THE BIG PICTURE: The government's purchasing rules encourage contracts with small businesses and other types of protected companies. The requirements are written into RFPs. Removing them often is a sign that the government prefers a particular company that fails to satisfy some qualification.

THE ANALYSIS: The government gave bidders exactly a week to submit their responses. It often takes longer to prepare a complete, competitive submission. "The new RFP. . . is, in our opinion, a procedural maneuver that now allows BARDA to issue a contract to SIGA," Wedbush Securities analysts wrote in a research note Tuesday.

The analysts "strongly" reiterated an "Outperform" rating on the stock, saying the contract, if awarded, calls for 1.7 million courses, valued at $500 million, with a potential follow-on contract valued at $2.8 billion. "We anticipate an ongoing annual demand of approximately 1.5 million doses to be worth $225 million in annual sales to SIGA," they wrote.

SIGA, based in New York, makes and supplies drugs used to treat and prevent infectious diseases including those in biological weapons.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,039.62 -14.09 -0.08%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs